Highlights from ASCO GU 2026: First-in-human Assessment of actinium-225-prostate-specific membrane antigen (225Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation Results of the Phase 1 PAnTHa Study
Phase 1 data show favorable safety and meaningful PSA responses with Trillium in heavily pretreated metastatic castration-resistant prostate cancer.
Read More